Rintodestrant

Selective estrogen receptor degrader

{{Drugbox | verifiedfields = changed | verifiedrevid = 477002123 | IUPAC_name = (2S)-2-[[4-[2-(1,1-dimethylethyl)-4,5-dihydro-1H-imidazol-1-yl]phenyl]methyl]-3-methylbutanoic acid | image = Rintodestrant.svg | image_size = 250px | image_alt = Chemical structure of Rintodestrant | width = | alt = | tradename = | synonyms = G1T48 | CAS_number = 2229010-77-2 | ATC_prefix = | ATC_suffix = | PubChem = 137349679 | DrugBank = | ChemSpiderID = 64835192 | UNII = | KEGG = | ChEMBL = 4297640 | ChemBLID = | SMILES = CC(C)C1=CC=C(C=C1)C2=NC(=NCC2)C(C)(C)C | StdInChI = 1S/C20H28N2O2/c1-14(2)19(23)15-7-9-16(10-8-15)18-12-13-22(20(18)21-11-17(18)20)3-4-5-6-21/h7-10,14H,3-6,11-13H2,1-2H3,(H,23,24) | StdInChIKey = }}

Rintodestrant is a selective estrogen receptor degrader (SERD) that is being investigated for the treatment of hormone receptor-positive breast cancer. It is a nonsteroidal compound that works by binding to the estrogen receptor and promoting its degradation, thereby inhibiting the growth of estrogen-dependent tumors.

Mechanism of Action

Rintodestrant functions by targeting the estrogen receptor alpha (ERα), which is a key driver in the proliferation of hormone receptor-positive breast cancer cells. Unlike traditional selective estrogen receptor modulators (SERMs) that block the receptor, SERDs like rintodestrant induce a conformational change in the receptor, leading to its degradation. This results in a reduction of estrogen receptor levels in the cell, thereby diminishing the estrogen signaling that promotes tumor growth.

Clinical Development

Rintodestrant is currently undergoing clinical trials to evaluate its efficacy and safety in patients with advanced or metastatic hormone receptor-positive breast cancer. Early-phase studies have shown promising results, with rintodestrant demonstrating significant antitumor activity and a favorable safety profile.

Pharmacokinetics

The pharmacokinetic profile of rintodestrant includes its absorption, distribution, metabolism, and excretion characteristics. It is designed to be orally bioavailable, allowing for convenient administration. The compound is metabolized primarily in the liver, and its metabolites are excreted via the renal and fecal routes.

Potential Benefits

Rintodestrant offers several potential advantages over existing therapies for hormone receptor-positive breast cancer. Its ability to degrade the estrogen receptor rather than merely blocking it may overcome resistance mechanisms associated with other treatments. Additionally, as an oral therapy, it provides a more convenient option for patients compared to injectable SERDs.

Challenges and Considerations

While rintodestrant shows promise, there are challenges in its development and clinical application. These include understanding the long-term effects of estrogen receptor degradation and managing any potential side effects. Ongoing research aims to address these issues and optimize the therapeutic use of rintodestrant.

Related Pages

• Breast cancer
• Estrogen receptor
• Selective estrogen receptor degrader
• Hormone therapy (oncology)